Member Info for Energyshares

AADi; Advenchem, Lilly Grant/Contract, Research funding.

C. Plummer,

Amgen; Servier Grant/Contract, Honoraria.

P. Loadman,

Avacta Grant/Contract, Paid consultant.

G. Lahu,

ThinkQ2 AG Employment.

Avacta Grant/Contract, Paid consultant.

H. S. Jones,

Avacta Grant/Contract, Paid consultant.

N. Kinnersley,

Avacta Grant/Contract, Paid consultant.

F. McLaughlin,

Avacta Employment.

C. Twelves,

MSD, Eisai, Daiichi-Sankyo, AstraZeneca, Pfizer, Lilly, Novartis and Gilead Grant/Contract, Travel, Advisory boards and research funding.

Abstract

Abstract is embargoed at this time.

CT188 / 16 - A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors

Add to My Itinerary

April 9, 2024, 9:00 AM - 12:30 PM Section 48

Presenter/Authors

U. Banerji1, N. Cook2, A. Anthoney3, R. Plummer4, W. D. Tap5, J. T. R. Evans6, L. D. Cranmer7, C. Plummer8, P. Loadman9, G. Lahu10, H. S. Jones9, N. Kinnersley11, F. McLaughlin12, C. Twelves8;

1The Institute of Cancer Research, Sutton, Sutton, United Kingdom, 2The Christie NHS Foundation Trust, Manchester, United Kingdom, 3The University of Leeds, Leeds, United Kingdom, 4Newcastle University, Newcastle, United Kingdom, 5Memorial Sloan Kettering Cancer Center, New York, NY, 6University of Glasgow, Glasgow, United Kingdom, 7University of Washington Fred Hutchinson Cancer Center, Seattle, WA, 8University of Leeds, Leeds, United Kingdom, 9University of Bradford, Bradford, United Kingdom, 10ThinkQ2 AG, Baar, Switzerland, 11Octa Consulting Group, Harpenden, United Kingdom, 12Avacta Therapeutics, London, United Kingdom

Disclosures

U. Banerji,

Phoenix Solutions; PharmEnable; Ellipses Pharma Grant/Contract, Advisory board.

AstraZeneca; Onyx; Chugai; BTG; Verastem Grant/Contract, Research funding.

N. Cook,

Roche; RedEx Grant/Contract, Advisory boards.

AstraZeneca, Orion, F. Hoffmann-La Roche Ltd, Taiho, GSK, Novartis, Starpharma, Bayer, Eisai, UCB, RedX Pharmaceuticals, Stemline Therapeutics, LOXO-oncology, Avacta, Boehringer Ingelheim, Merck, Tar Grant/Contract, Research funding.

A. Anthoney, None.

R. Plummer,

Pierre Faber, Bayer, Novartis, BMS, Ellipses, Immunocore, Genmab, Astex Therapeutics, MSD, Nerviano, AmLo, Incyte, Cybrexa Benevolent AI and Sanofi Aventis Grant/Contract, Advisory board.

Alligator Biosciences, GSK, Onxeo, SOTIO Biotech AG, and AstraZeneca Grant/Contract, IDMC honoraria.

AstraZeneca, Novartis, Bayer, MSD and BMS Grant/Contract, Travel, Educational talks with grant/travel.

W. D. Tap,

Atropos; Certis Stock.

AmMax; Amgen; BioAtla; Boehringer Ingelheim; Cogent; Daiichi Sankyo; Deciphera; InhibRx; Servier; Per Events; PVI Grant/Contract, Research Funding/Advisory board.

J. T. R. Evans,

Ascelia, Astra Zeneca, Bayer, Bicycle Therapeutics, Bristol-Myers Squibb, Celgene, Eisai, Karus Therapeutics, Medivir, MSD, Otsuka, Roche, and Seagen Grant/Contract, Honoraria.

Astra Zeneca, Ascelia, Bayer, Bristol Myers Squibb, Celgene, Eisai, Nucana, MSD, Roche, Medivir, and United Medical Grant/Contract, Speaker fees.

Bristol-Myers Squibb; Roche; MSD; Pierre-Fabre; Celgene; Bayer Travel.

Astra Zeneca, Basilea, Bayer, Celgene, MiNa Therapeutics, Roche, Pfizer, Sierra, Lilly, Eisai, GSK, Novartis, Bicycle Therapeutics, Johnson and Johnson, CytomX, Vertex, Plexxikon, Boehringer, Athinex Grant/Contract, Clinical trial grants to institution.

L. D. Cranmer,

Blueprint Medicines Grant/Contract, Advisory board.

AADi; Advenchem, Lilly Grant/Cont

🤡 voting

"Without additional funds in excess of £20m, the Company would not have been able to progress any of its pre-clinical pipeline, which we believe will drive significant future shareholder value well beyond AVA6000.

Stop being a greedy twat and get a BP partner on board ASAP most LTH’s would like some professional help maximising this platform.

Put a stop to your silly games…

Shocking one guy on twitter lost all his investment his wife and kid, he is in a dark place other PI’s pleading with him to not do anything stupid…

Then there is Smith & Gardiner laughing in the City.

Holy grail in Cancer treatment.

What about mental health ?

They both need to go,funding could of been sorted months ago.

It’s not just PI’s, Wetherby’s Bonnie & Clyde have had over, just two weeks earlier they

RNS’s this:

Award Scheme, ordinary shares of 10p each in the Company ("Ordinary Shares") up to a value of £3,000 per employee will be issued at the prevailing middle market price at the close of business on 14 February 2024 to all eligible employees. These shares awarded will form part of the employee's remuneration package.

Imagine getting a bonus for all your hard work then your boss reduces by 50% two weeks later.

Hang your heads in shame Smith & Gardiner do the right thing and resign.

Only patients that attend MSK and Fred Hutch will know about it.

Oncologists all over USA will probably just stick to Standard dox for their patients.

That should change once data revealed at AACR…

H&L £50 min at 0.50p

What’s the max you can invest ?

Dear Avacta Retail share holders we would like to apologise for raising in the REX offer £6.8 million@ 50p for 13,600,000 shares.

When 15 months ago we could of sold 13,600,000 shares @ 95p and raised £12,920,000

Our resignations to follow.

Everyone print 2 copies and send it to them.

Keep this top of board so they know it’s coming

Dear Avacta Retail share holders we would like to apologise for raising in the REX offer £6.8 million@ 50p for 13,600,000 shares.

When 15 months ago we could of sold 13,600,000 shares @ 95p and raised £12,920,000

Our resignations to follow.

Everyone print 3 copies and send it to them.

Like AACR why all cloak and dagger,

In December we want to present at a major conference , everyone then speculates.

Why not just say we want to present at AACR in April with C7 data.

Done investors and city happy.

If the mad professor dropped the trial news from that RNS last week the SP would of bounced back above £1.20 +

But the nutty professor saved it to hide his 💩 show today…

Time to go…..

BITL,

I thought all patients were end of life.

18 months plus ….wow

With all that’s gone on today

Just trying to digest todays RNS not the sell out part but the trial info:

Can’t get my head around this

59-year-old with tumour shrinkage treated at 160 mg/m2 this is cohort 3 started July 22 finished Sep 22 are they saying he has been on the trial for 18 months ???

If true this is massive….

The starting dose for cohort 1 was 80 mg/m2 of AVA6000, which is equivalent to 54 mg/m2 of doxorubicin which is just below the standard dose for doxorubicin. The Safety Data Monitoring Committee ("SDMC") reviewed the data from cohort 1 in February 2022 and recommended that the dose be escalated to 120 mg/m2. The SDMC approved dose escalation to 120 mg/m2 in a second cohort, 160 mg/m2 in a third cohort, 200mg/m2 in a fourth cohort, 250mg/m2 in a fifth cohort, 310mg/m2 in a sixth cohort and 385mg/m2 in a seventh and final cohort.

Todays RNS

Deepening tumour shrinkage has been observed in two patients with disease predicted to have high FAP expression:

· A 59-year-old male with the diagnosis of undifferentiated pleomorphic sarcoma, treated at 160 mg/m2 on a three-weekly dosing ("Q3W"), resulted in a Partial Response with a duration of greater than 6 months and a tumour volume reduction of ~65%. Treatment is ongoing, with high FAP expression observed in the tumour tissue and a favourable PK profile with reduction in AUC which permits dosing for 7 additional cycles (~21 weeks)

RNS Number : 5475Q

Avacta Group PLC

29 June 2022

Avacta's Safety Data Monitoring Committee (SDMC), comprised of clinicians currently recruiting patients, has completed its review of the safety data from the second cohort dosed with AVA6000 at 120mg/m2 in the ongoing Phase I trial. Following this review, the SDMC has recommended that the clinical trial continues as planned and escalates to the next dose of AVA6000 at 160mg/m2.

Cohort 3 finished Sep 2022

So the 59 year old with 65% shrinkage was

160 mg/m2 on a three-weekly

was cohort 3 great news.

If FDA approved after phase 2,

Phase 3 is monitoring while on the market.

264 million shares in circulation don’t know how many II’s or employees have.

So Pi’s REX Offer shall not exceed £6.8 million@ 50p

13,600,000 shares divided by ? Number of Pi’s

Does any one know how many shares Pi ‘s own ?

“ . You should never invest more than 10% of your portfolio in one stock”

Like you did with ODX 🤡

Trolls looked spooked 🤡🤡🤡

Has bad teeth double bluffed the short crew ….